Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.

Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

Gallwitz, Baptist · 2011 · Drugs

Abstract

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 receptor agonists acting on the GLP-1 receptor, exenatide and liraglutide are available in many countries. In type 2 diabetes treatment, incretin-based therapies are attractive and more commonly used because of their mechanism of action and safety profile. Stimulation of insulin secretion and inhibition of glucagon secretion by these agents occur in a glucose-dependent manner. Therefore, incretin-based therapies have no intrinsic risk for hypoglycaemia. Furthermore, GLP-1 receptor agonists allow weight loss and lower systolic blood pressure. This review gives a brief overview of the mechanism of action and summarizes the clinical data available on exenatide and liraglutide as established substances. It further highlights the clinical study data of exenatide once weekly as the first long-acting GLP-1 receptor agonist and covers other new long acting GLP-1 receptor agonists currently in clinical development. The placement of GLP-1 receptor agonists in the treatment algorithm of type 2 diabetes is discussed.

Overview

Integrity signals

Registry

Crossref · 10.2165/11592810-000000000-00000

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 99 references

Research works printed but not linked: 3

  1. Klonoff, 2008, Curr Med Res Opin, 24, 275, 10.1185/030079907X253870 · doi:10.1185/030079907x253870 · Paper page
  2. Ahmad, 2008, N Engl J Med, 358, 1970
  3. Garber, 2008, J Fam Pract, 57, S10

Cited by

See all 142

Metadata

Authors
Gallwitz, B.
Affiliations
University of Tübingen (DE)
Corresponding author
Gallwitz, Baptist
Venue
Drugs
Published
2011-09
Volume
71
Issue
13
Pages
1675-1688
ISSN
0012-6667 (ISSN-L)
OpenAlex
W188703145
Cited by
142
References
99
Citations by year
2026: 3 · 2025: 2 · 2024: 11 · 2023: 9 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 11 · 2016: 9 · 2015: 11 · 2014: 12 · 2013: 20 · 2012: 22
FWCI
2.53
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, exenatide once weekly, long-acting GLP-1 receptor agonists, incretin-based therapy, insulin secretion, glucagon secretion, weight loss, blood pressure reduction, treatment algorithm
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Peptides, Venoms, Receptors, Glucagon, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents. https://app.cochat.ai/papers/10.2165/11592810-000000000-00000
The paper
Gallwitz, B. (2011). Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents. Drugs. https://doi.org/10.2165/11592810-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.